Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial

Study limitation reported by the research below: “No clinical efficacy endpoint (e.g., laboratory-confirmed influenza) was included — conclusions are based solely on immunogenicity surrogates.”